{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:59Z","timestamp":1791404399633,"version":"4.3.3"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyze the impact of prior therapies on outcomes with selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in 402 patients with relapsed\/refractory multiple myeloma (RRMM) in the phase 3 BOSTON trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Post hoc analysis of progression\u2010free survival (PFS), overall survival (OS), and safety for lenalidomide\u2010refractory, proteasome inhibitor (PI)\u2010na\u00efve, bortezomib\u2010na\u00efve, and one prior line of therapy (1LOT) patient subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At a median follow\u2010up of over 28\u2009months, clinically meaningful improvements in PFS were noted across all groups with SVd. The median SVd PFS was longer in all subgroups (lenalidomide\u2010refractory: 10.2 vs. 7.1\u2009months, PI\u2010na\u00efve: 29.5 vs. 9.7; bortezomib\u2010na\u00efve: 29.5 vs. 9.7; 1LOT: 21.0 vs. 10.7; <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). The lenalidomide\u2010refractory subgroup had longer OS with SVd (26.7 vs. 18.6\u2009months; HR 0.53; <jats:italic>p<\/jats:italic>\u2009=\u2009.015). In all subgroups, overall response and \u2265very good partial response rates were higher with SVd. The manageable safety profile of SVd was similar to the overall patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>With over 2\u2009years of follow\u2010up, these clinically meaningful outcomes further support the use of SVd in patients who are lenalidomide\u2010refractory, PI\u2010na\u00efve, bortezomib\u2010na\u00efve, or who received 1LOT (including a monoclonal antibody) and underscore the observed synergy between selinexor and bortezomib.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14223","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T02:05:40Z","timestamp":1714615540000},"page":"242-252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: Extended follow\u2010up subgroup analysis of the <scp>BOSTON<\/scp> trial"],"prefix":"10.1111","volume":"113","author":[{"given":"Maria\u2010Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Hospital Universitario de Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Interdisciplinary Cancer Center, University of Freiburg, Faculty of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"University of Potiers and CHU  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes Gironella","family":"Mesa","sequence":"additional","affiliation":[{"name":"University Hospital Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna, Ser\u00e0gnoli Institute of Haematology, Bologna University School of Medicine  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bianco","sequence":"additional","affiliation":[{"name":"Menarini Group  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marino","family":"Merlo","sequence":"additional","affiliation":[{"name":"Menarini Group  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles la","family":"Porte","sequence":"additional","affiliation":[{"name":"Menarini Group  Machelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital Hotel\u2010Dieu  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12430"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00903-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30143-6"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2019.103504"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24451"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.11.022"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.7080"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12969"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0553"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12428"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2632"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0488"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.279.279"},{"key":"e_1_2_10_22_1","volume-title":"Prescribring Information","author":"Xpovio\u00ae","year":"2022"},{"key":"e_1_2_10_23_1","volume-title":"Prescribing Information","author":"Nexpovio\u00ae","year":"2023"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.709"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.06.001"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01071-9"},{"key":"e_1_2_10_28_1","volume-title":"NICE DSU Technical Support Document 16: Adjusting Survival Time Estimates in the Presence of Treatment Switching","author":"Latimer NR","year":"2014"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0709-9"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.186"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01021-3"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.018"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01611-7"},{"key":"e_1_2_10_36_1","volume-title":"Prescribing information","author":"Kyprolis\u00ae","year":"2022"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:26:30Z","timestamp":1719980790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/ejh.14223"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14223","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}